Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaBen® in adolescent schizophrenia
NCT01908192Phase 3Terminated
- Sponsor
- SyneuRx
- Start
- Jun 2014
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing NaBen® Arm with Placebo Arm (2 arms). Primary endpoint: Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at 6 weeks. Started Jun 2014; status: terminated.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01908192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908192.